Literature DB >> 28479121

Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: A review.

V Danel-Brunaud1, L Touzet2, L Chevalier2, C Moreau3, D Devos4, S Vandoolaeghe5, L Defebvre3.   

Abstract

Amyotrophic lateral sclerosis (ALS) is not a curable disease, but it is treatable. By definition, much of the care provided to ALS patients is palliative, even though active life-sustaining strategies are available to prolong survival. Healthcare professionals must develop communication skills that help patients cope with the inexorable progression of the disease and the inevitability of death. Symptomatic treatments as well as respiratory insufficiency and nutritional life-sustaining therapies must be regularly evaluated as the disease progresses, without losing sight of the burden placed on the patient's non-professional caregivers. The decision-making process regarding tracheostomy with invasive ventilation (TIV) is of greater complexity. Providing full information is crucial. Several long interviews are necessary to explain, discuss and allow assimilation of the information. Also, physicians should be careful not to focus exclusively on the biomedical aspects of disease, as ALS patients generally welcome the opportunity to discuss end-of-life issues with their physicians. Psychological factors, education level and cognitive status (especially the level of executive dysfunction) have a major influence on their decisions. However, as many patients do not complete advance directives with regard to TIV, advance care planning may instead be suggested in anticipation of emergency interventions. This should be discussed by healthcare professionals and the patient, and based on the wishes of the patient and caregiver(s), and communicated to all healthcare professionals. Many healthcare professionals are involved in the management of an ALS patient: they include not only those at ALS centers who provide diagnosis, follow-up and treatment initiation (particularly for respiratory and nutritional care), but also the medical and social care networks involved in disability support and home care. Specialist palliative care teams can work in partnership with ALS centers early in the course of the disease, with the center coordinating information-sharing and collaborative discussions.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ALS; End of life; Ethical considerations; Motor neuron disease; Palliative care; Treatment restriction; Treatment withdrawal

Mesh:

Year:  2017        PMID: 28479121     DOI: 10.1016/j.neurol.2017.03.032

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

Review 1.  Talking about the end of life: communication patterns in amyotrophic lateral sclerosis - a scoping review.

Authors:  Anke Erdmann; Celia Spoden; Irene Hirschberg; Gerald Neitzke
Journal:  Palliat Care Soc Pract       Date:  2022-03-15

2.  Palliative Care Nursing in Australia and the Role of the Registered Nurse in Palliative Care.

Authors:  Rajkumar Cheluvappa; Selwyn Selvendran
Journal:  Nurs Rep       Date:  2022-08-12

Review 3.  Communication Matters-Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis.

Authors:  Katharina Linse; Elisa Aust; Markus Joos; Andreas Hermann
Journal:  Front Neurol       Date:  2018-07-27       Impact factor: 4.003

Review 4.  Public Engagement and Neurology: An Update.

Authors:  Luigi Lavorgna; Francesco Brigo; Sabrina Esposito; Gianmarco Abbadessa; Maddalena Sparaco; Roberta Lanzillo; Marcello Moccia; Matilde Inglese; Luca Bonfanti; Francesca Trojsi; Emanuele Spina; Antonio Russo; Pasquale De Micco; Marinella Clerico; Gioacchino Tedeschi; Simona Bonavita
Journal:  Brain Sci       Date:  2021-03-28

Review 5.  Cognitive and Behavioral Manifestations in ALS: Beyond Motor System Involvement.

Authors:  Robert Rusina; Rik Vandenberghe; Rose Bruffaerts
Journal:  Diagnostics (Basel)       Date:  2021-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.